KK体育
EN
中文
EN
KK体育: About Us
About Us
Overview
History
Honor
KK体育:Contact Us
Continuous innovation for better life
Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is an innovation-driven pharmaceutical company integrating the R&D, manufacturing, and sales of drugs. As a principal subsidiary of Hansoh Pharma (03692.HK), the Company is committed to improving human health through continuous innovation, particularly in the treatment of major diseases including the areas of oncology, infections, the central nervous system, metabolic disorders, and autoimmune disease.
KK体育:Innovation
Innovation
KK体育:Achievements
Therapy Areas
R&D Platforms
KK体育:R&D Capability
Continuous innovation for better life
Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
Products
Products
KK体育:Key Products
Continuous innovation for better life
After more than 20 years of continuous investment in R&D, Jiangsu Hansoh Pharma has marketed 7 innovative drugs and has over 30 innovative drug programs in different clinical stages with over 50 clinical trials in progress, forming a rich pipeline.
Manufacturing
Manufacturing
KK体育:Lean Manufacturing
KK体育:Quality Management
Continuous innovation for better life
Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and by using advanced production equipment.
Marketing Service
Marketing Service
KK体育:Market Coverage
KK体育:Hengte Pharmacy
Continuous innovation for better life
Under the new normal in the pharmaceutical industry, Jiangsu Hansoh Pharma endeavors to be proactive in the implementation of national policies and the innovation of business structure.
News
News
KK体育:Press Releases
KK体育:Media Center
Hansoh Pharma updates
Find the latest and most complete information about Hansoh Pharma!
KK体育:Social Responsibility
Social Responsibility
KK体育:Responsible Governance
Green Development
Public Charity
Responsibility integrity diligence innovation
Jiangsu Hansoh Pharma always adheres to the core values of responsibility, integrity, diligence, and innovation, serving human health with scientific and technological innovation, and assuming corporate social responsibility with accountable behavior in conducting business.
Careers
Careers
Work with Us
Work with us
We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!
Search
中文
EN
About Us
Back
Overview
History
Honor
Contact Us
Innovation
Back
Achievements
Therapy Areas
KK体育:R&D Platforms
KK体育:R&D Capability
Products
Back
Key Products
KK体育:Manufacturing
Back
Lean Manufacturing
KK体育:Quality Management
Marketing Service
Back
Market Coverage
KK体育:Hengte Pharmacy
News
Back
KK体育:Press Releases
KK体育:Media Center
KK体育:Social Responsibility
Back
Responsible Governance
Green Development
Public Charity
Careers
Back
Work with Us
KK体育:
Related Links
Press Releases
Press Releases
KK体育:Media Center
Home
News
Press Releases
Year
2024
2023
2022
2021
2020
Search
Ranked Third in China! Brand Value of Hansoh Pharma Reaches New High
Recently, on the occasion of the Fifth China Brand Day, seven national ministries and commissions, including Xinhua News Agency and SASAC News Center,...
2021.05.13
Priority Review! Hansoh Pharma Applies for Marketing Approval of First-Line Treatment Indication for Ameile
Recently, the marketing approval application of Ameile (Almonertinib Mesilate Tablets), Class 1 innovative drug independently developed by Jiangsu Ha...
2021.05.13
Achieve Excellence with Amelie: Hansoh Pharma's Innovative Approach to Precision Diagnosis and Treatment of Lung Cancer
Recently, "Create Excellence in China with Ameile - 2nd CSCO Hansoh Pharma Lung Cancer Precision Diagnosis and Treatment Forum" was held simultaneousl...
2021.05.12
Ease for Patients | List of Medical Institution Providing Ameile and Hansoh Xinfu Available on NHSA Website
Urgent clinical needs and low substitutability In order to facilitate timely purchase of NRDL (National Reimbursement Drug List) negotiated drugs by t...
2021.05.01
Strive for Healthy China!
Efforts bring happiness; hard work leads to great results On the occasion of the International Workers' Day Hansoh Pharma salutes all hardworking work...
2021.05.01
Thumbs-up from People's Daily! Hansoh Pharma's Ameile Won Title of Breakthrough New Drug of the Year
On April 28, People's Daily Health Client and Health Times published a series of honorary lists including the 13th Health China Forum · Breakthrough N...
2021.04.29
World Intellectual Property Day | Protecting IP Assets, Hansoh Pharma is in Action
April 26, 2021 marks the 21st World Intellectual Property Day. Hansoh Pharma adheres to the innovation-driven development strategy. Since its inceptio...
2021.04.26
Earth Day | Practicing Green Development, Hansoh Pharma on the Way
4.22 Earth Day Every year on April 22, Earth Day is a campaign dedicated to the protection of the world's environment. It aims to raise people's awar...
2021.04.22
Light up the hope of life - Hansoh Pharma paves the road to cure cancer with technological innovation
April 17 World Cancer Day Over the past 20 years, great progress has been made in tumor diagnosis and treatment, from chemotherapy alone to targeted t...
2021.04.17
Expand first-line treatment with combined chemotherapy – Another registered clinical study of almonertinib was approved
Recently, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma" or "Company") received the Notice of Approval for Drug Clinical Trial ("Notic...
2021.04.17
Gold shines brighter after coming out from fire丨Hansoh Xinfu's real-world clinical effect is highly recognized
Recently, the real-world clinical study data of Hansoh Xinfu (Flumatinib Mesylate Tablets) was shared at Hansoh's Spring Forum on Blood 2021. Attendin...
2021.04.17
Another Major Breakthrough | Ameile of Hansoh Pharma, Tapping Maximum Potential for Patients' Health
"The release of the positive results of the phase III clinical study of Ameile is a major breakthrough in the field of targeted therapy for lung cance...
2021.03.30
1
KK体育: 2
...
KK体育: 7
8
9
10
KK体育: 11
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7fDzSfyJvbjbD",ck:"K9y7fDzSfyJvbjbD"});
k1体育(中国)官方网站app
k1体育·(中国)官方网站-手机APP下载
k1体育·(中国)平台官网
k1体育平台(中国)官网 - ios/安卓/手机版app下载
k1·体育(中国)官方网站-ios/安卓/手机版app下载
EN
